REGULATION OF HEPATOCARCINOGENESIS BY ACYCLIC RETINOID
无环维A酸对肝癌发生的调节作用
基本信息
- 批准号:11670490
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1999
- 资助国家:日本
- 起止时间:1999 至 2001
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Retinoid inhibit the tumor promotion phase of mutistep carcinogenesis. We have conducted investigations of chemoprevention of hepatocellular carcinoma by retionoids and confirmed the clinical effects of acyclic retionid, a synthetic retinoid analog, on second primary hepatocarcinogenesis. Interferons ( IFNs )-α and - β also induce apoptosis of hepatocellular carcinoma ( HCC ) cells and are used clinically in the prevention of HCC. Acyclic retinoid enhanced anti-tumor effects of not only IFN-β but also IFN-α, however, natural retinoic acid ( all-trans and 9-cis retinoic acid ) failed to exert such effect. This combination effect was likely due to enhanced apoptosis Mnduction as characterized by DNA fragmentation and chromatin condensation. Pretreatment of the HCC cells with acyclic retinoid followed by IFN-β, but not the converse, induced such cytotoxic effect. Acyclic retinoid increased the expression of type 1 IFN receptor ( IFNR ) and inclusion with anti-type 1 IFNR antibody abolished the synergistic growth suppression by the combination. Moreover, the retinoid up-regulated the expression and DNA-binding activity of STAT1, an intracellular signal transducing molecule of IFNR. Thus, acyclic retinoid seemed to enhance the sensitivity of HCC cells to IFN-β and thereby promoted the cancer cell death. These results suggest a future clinical use of the combination of acyclic retinoid and IFN-β in the biochemoprevention of HCC. We evaluate these results as very important to establish cancer chemoprevention with retionids and to develop novel cancer chemopreventive agents.
维甲酸抑制肿瘤促进期的多步致癌作用。我们已经进行了维甲酸类化合物化学预防肝细胞癌的研究,并证实了非环维A酸类类似物对第二原发癌发生的临床效果。干扰素(IFN)-α和-β也可诱导肝细胞癌细胞的凋亡,并被用于临床预防肝癌。非环维A酸类化合物不仅能增强干扰素-β和干扰素-α的抗肿瘤作用,而且天然维甲酸(全反式和9-顺式维甲酸)不能发挥这种作用。这种联合作用可能是由于促进了以DNA片段化和染色质凝集为特征的细胞凋亡。用去环维A酸预处理肝癌细胞后再用干扰素-β,而不是相反,诱导了这种细胞毒效应。非环类维甲酸可增加I型干扰素受体(IFNR)的表达,并与抗I型IFNR抗体包合,可消除联合作用对细胞生长的协同抑制作用。此外,维甲酸还上调了IFNR细胞内信号转导分子STAT1的表达和DNA结合活性。因此,去环维A酸似乎增强了肝癌细胞对干扰素-β的敏感性,从而促进了癌细胞的死亡。这些结果提示,去环维A酸类药物和干扰素-β联合应用于肝细胞癌的生化学预防中具有潜在的临床应用前景。我们评估这些结果对于建立用维拉西林进行癌症化学预防和开发新的癌症化学预防药物非常重要。
项目成果
期刊论文数量(73)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Yasuda I, et al.: "Acyclic Retinoid Induces Partial Differentfation, Down-Regulates, Telomerase Revcrse Trauscriptase mRNA Expression and Telomerase Activity, and Induces Apoptosis in Human Hepatoma-Derived Cell Lines"J Hepatol. (in press).
Yasuda I 等人:“无环视黄醇在人肝癌衍生细胞系中诱导部分分化、下调、端粒酶逆转录酶 mRNA 表达和端粒酶活性,并诱导细胞凋亡”J Hepatol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Muto,Y, Moriwaki,H, Saito,A.: "Prevention of second primary tumors by an acyclic retinoicl in patients with hepatocellular carcinoma"N Engl J Med. 340. 1046-1047 (1999)
Muto,Y,Moriwaki,H,Saito,A.:“通过无环视黄醇预防肝细胞癌患者的第二原发肿瘤”N Engl J Med。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kimura,K., Ando,K., Ohnishi,H., Ishikawa,T., Kakumu,S., Takemura,M., Muto,Y., Moriwaki,H.: "Immunopathogenesis of hepatic fibrosis in chronic inflammatory liver disease. Novel fibrosis model in conA induced liver injury."Int Immunol. 11. 1491-1500 (1999)
Kimura,K.、Ando,K.、Ohnishi,H.、Ishikawa,T.、Kakumu,S.、Takemura,M.、Muto,Y.、Moriwaki,H.:“慢性炎症性肝病中肝纤维化的免疫发病机制
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kimura,K., Ando,K., Tomita,E., Ohnishi,H., Ishikawa,T., Kakumu,S., Muto,Y., Moriwaki,H.: "Elevated intracellular IFN- γ- levels in circulating CD8+lymphocytes in patients with fulminant hepatitis"J Hepatol. 31. 579-583 (1999)
Kimura, K.、Ando, K.、Tomita, E.、Ohnishi, H.、Ishikawa, T.、Kakumu, S.、Muto, Y.、Moriwaki, H.:“细胞内 IFN-γ- 水平升高暴发性肝炎患者循环 CD8+ 淋巴细胞中的“J Hepatol. 31. 579-583 (1999)”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nagaki,M., Sugivama,A., Osawa,Y., Naiki,T., Nakashima,S., Nozawa,Y., Moriwaki,H.f.: "Lethal hepatic apoptosis mediated by tumor necrosis factor receptor, unlike Fas-mediated apoptosis, requires hepatocyte sensitization in mice."J Hepatol. 31. 997-1005 (19
Nagaki,M.、Sugivama,A.、Osawa,Y.、Naiki,T.、Nakashima,S.、Nozawa,Y.、Moriwaki,H.f.:“肿瘤坏死因子受体介导的致死性肝细胞凋亡,与 Fas 介导的细胞凋亡不同
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MORIWAKI Hisataka其他文献
MORIWAKI Hisataka的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MORIWAKI Hisataka', 18)}}的其他基金
Combination chemoprevention of hepatocellular carcinoma with acyclic retinoid by targeting RXRαphosphorylation
靶向 RXRα 磷酸化的无环维A酸联合化学预防肝细胞癌
- 批准号:
21590838 - 财政年份:2009
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Strategy for chemoprevention of digestive cancers by targeting abnormalities in receptor tyrosine kinases and nuclear receptors
针对受体酪氨酸激酶和核受体异常的消化道癌症化学预防策略
- 批准号:
19590720 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Strategy for the chemoprevention of hepatocellular carcinoma by targeting phosphorylated RXRa
靶向磷酸化 RXRa 的肝细胞癌化学预防策略
- 批准号:
17015016 - 财政年份:2005
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
The role of cytokine cascade in impaired liver regeneration and development of candidate pharmaceutical(s) to regulate this mechanism
细胞因子级联在肝脏再生受损中的作用以及调节该机制的候选药物的开发
- 批准号:
16590585 - 财政年份:2004
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Retinoid upregulates the sensitivity of cancer cells to a cytokine by inducing the cytokine receptor
类维生素A通过诱导细胞因子受体上调癌细胞对细胞因子的敏感性
- 批准号:
13557048 - 财政年份:2001
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
MECHANISMS OF CLONAL DELETION OF HEPATOCELLULAR CARCINOMA BY ACYCLICRETINOID
环状维A酸克隆删除肝细胞癌的机制
- 批准号:
10557055 - 财政年份:1998
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
MECHANISMS OF REGULATION AND CONTROL OF HEPATOCARCINOGENESIS BY ACYCLIC RETINOID
无环维A酸调控肝癌发生的机制
- 批准号:
08670576 - 财政年份:1996
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GENOMIC MECHANISMS OF REGULATION AND CONTROL OF HEPATOCARCINOGENESIS BY RETINOIDS
类维生素A调控肝癌发生的基因组机制
- 批准号:
05670463 - 财政年份:1993
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Dissecting the roles of iron and hemojuvelin in hepatocellular carcinoma
剖析铁和血幼素在肝细胞癌中的作用
- 批准号:
478251 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Operating Grants
Impact of sarcopenia and creation of novel therapeutic targets by immunotherapeutic resistance mechanisms in hepatocellular carcinoma
肌少症的影响以及通过免疫治疗耐药机制创建新的治疗靶点对肝细胞癌的影响
- 批准号:
23K08106 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of transcatheter arterial embolization for controlling hypoxia in hepatocellular carcinoma
经导管动脉栓塞控制肝细胞癌缺氧的研究进展
- 批准号:
23K07075 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
NASH-肝细胞癌免疫治疗反应的决定因素
- 批准号:
10735947 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Targeting Ischemia-Induced Autophagy Dependence in hepatocellular Carcinoma through Image-guided Locoregional Therapy
通过图像引导局部治疗靶向肝细胞癌中缺血诱导的自噬依赖性
- 批准号:
10585078 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Investigating the Metabolic Role of Vagal Insulin Signaling in Hepatocellular Carcinoma
研究迷走神经胰岛素信号在肝细胞癌中的代谢作用
- 批准号:
495140 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Miscellaneous Programs
Impact of TA-HEV expression on tumor microenvironment in hepatocellular carcinoma
TA-HEV表达对肝细胞癌肿瘤微环境的影响
- 批准号:
23K19513 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma
纤维板层肝细胞癌融合癌蛋白治疗靶向中心
- 批准号:
10826323 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Define the oncogenic role of Plk1 during hepatocellular carcinoma development using a genetically modified mouse model
使用转基因小鼠模型定义 Plk1 在肝细胞癌发展过程中的致癌作用
- 批准号:
10729603 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma
一种图像引导免疫治疗和热疗装置,用于克服晚期肝细胞癌的肿瘤免疫障碍
- 批准号:
10585715 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别: